JSW
NBIX icon

Journey Strategic Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Journey Strategic Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310K Buy
2,355
+464
+25% +$61.6K 0.01% 528
2025
Q4 		$268K Buy
1,891
+80
+4% +$11.6K 0.01% 553
2025
Q3 		$254K Buy
+1,811
New +$245K 0.01% 553

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Journey Strategic Wealth's NBIX Position: Q1 2026 in Review

Journey Strategic Wealth increased its Neurocrine Biosciences (NBIX) stake by 25% in Q1 2026, buying an estimated $61.6K and bringing the position to 2,355 shares worth $310K. The position accounts for 0.01% of the portfolio, ranked #528.

Journey Strategic Wealth first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Journey Strategic Wealth held 2,355 shares of Neurocrine Biosciences worth $310K as of Q1 2026.
  • Journey Strategic Wealth bought 464 Neurocrine Biosciences shares in Q1 2026, an estimated $61.6K.
  • Neurocrine Biosciences made up 0.01% of Journey Strategic Wealth's portfolio in Q1 2026, its #528 holding.
  • Journey Strategic Wealth first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.